Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 4/20 | 0.41 |
| ▸ | SLC19A1 | P41440 | 3/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506392 | 1.00 | KDM4E (0.52) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL501841 | 0.91 | KDM4E (0.45) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL30001202 | 0.91 | ALOX15 (0.46) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL502389 | 0.91 | ALOX15 (0.46) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL30677181 | 0.91 | KDM4E (0.45) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL15247750 | 0.90 | KDM4E (0.44) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL12862399 | 0.87 | KDM4E (0.41) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL7677588 | 0.87 | ALOX15 (0.46) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL21251503 | 0.86 | ALOX15 (0.46) | KDM4EALDH1A1HPGDMAPK1HSD17B10 | |
| SCHEMBL11888309 | 0.85 | ALOX15 (0.45) | KDM4EALDH1A1HPGDMAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| JP-4728487-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| JP-2002539197-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1163219-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2001-12-19 | — | — | EP | claimed |
| WO-2000055134-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2000-09-21 | — | — | WO | claimed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
| WO-2022150561-A1 | STABLE SOLUTIONS OF IMMUNOMODULATORY IMIDE COMPOUNDS FOR PARENTERAL USE | STARTON THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| US-20220218687-A1 | Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use | STARTON THERAPEUTICS, INC. | 2022-07-14 | — | — | US | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-9522899-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-9522899-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20110021567-A1 | PREPARATION OF LENALIDOMIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-01-27 | — | — | US | disclosed |
| WO-2010139266-A1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010056384-A1 | LENALIDOMIDE SOLVATES AND PROCESSES | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009114601-A2 | PREPARATION OF LENALIDOMIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-09-17 | — | — | WO | disclosed |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | CELGENE CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-6380239-B1 | FOR THERAPY OF ARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, REPERFUSION INJURY, INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE COLITIS, SYSTEMIC LUPUS ERYTHREMATOSIS, SCLERODERMA, APHTHOUS ULCERS, ASTHMA | CELGENE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| EP-1163219-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000055134-A1 | SUBSTITUTED 1-OXO- AND 1,3-DIOXOISOINDOLINES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR REDUCING INFLAMMATORY CYTOKINE LEVELS | CELGENE CORPORATION (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | KDM4E 2658/4885ALDH1A1 2539/4885HPGD 4691/4885 |
| US-20220218687-A1 | Stable Solutions of Immunomodulatory Imide Compounds for Parenteral Use | IL2, MYD88, MALT1 | KDM4E 602/4885ALDH1A1 2825/4885HPGD 513/4885 |
| US-20110021567-A1 | PREPARATION OF LENALIDOMIDE | RPS27A, PDCD2L, PML | KDM4E 806/4885ALDH1A1 3535/4885HPGD 2457/4885 |
| US-20070105903-A1 | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs | VEGFA, FLT4, FLT1 | KDM4E 1098/4885ALDH1A1 2713/4885HPGD 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.